The coagulation factors fibrinogen, thrombin, and factor XII in inflammatory disorders-a systematic review

Frontiers in Immunology

Volumn 9, Issue JUL, 2018, Pages

  Göbel, Kerstin ^a   Eichler, Susann ^a   Wiendl, Heinz ^a   Chavakis, Triantafyllos ^b   Kleinschnitz, Christoph ^c   Meuth, Sven G ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Coagulation factors; Contact system; Factor XII; Fibrinogen; Neuroinflammation; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 12; CD11B ANTIGEN; CD18 ANTIGEN; CYCLIC AMP; EPIDERMAL GROWTH FACTOR; FIBRINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; UROKINASE RECEPTOR; BLOOD CLOTTING FACTOR;

BLOOD CLOTTING; COLITIS; GENE MUTATION; HEMOSTASIS; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; KALLIKREIN KININ SYSTEM; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; THROMBOSIS; ANIMAL; BLOOD; DISEASE PREDISPOSITION; META ANALYSIS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DISEASE SUSCEPTIBILITY; FACTOR XII; FIBRINOGEN; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; THROMBIN;

EID: 85050452386     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01731     Document Type: Review

References (101)

1. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature (1964) 202:498-9. doi:10.1038/202498a0
2. Schoenmakers SH, Reitsma PH, Spek CA. Blood coagulation factors as inflammatory mediators. Blood Cells Mol Dis (2005) 34(1):30-7. doi:10.1016/j.bcmd.2004.09.001
3. McMichael M. New models of hemostasis. Top Companion Anim Med (2012) 27(2):40-5. doi:10.1053/j.tcam.2012.07.005
4. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science (1991) 253(5022):909-12. doi:10.1126/science.1652157
5. Lippi G, Favaloro EJ, Franchini M, Guidi GC. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost (2009) 35(1):9-22. doi:10.1055/s-0029-1214144
6. Strukova SM. Thrombin as a regulator of inflammation and reparative processes in tissues. Biochemistry (Mosc) (2001) 66(1):8-18. doi:10.1023/A:1002869310180
7. Mackman N. The many faces of tissue factor. J Thromb Haemost (2009) 7(Suppl 1):136-9. doi:10.1111/j.1538-7836.2009.03368.x
8. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol (2012) 34(1):43-62. doi:10.1007/s00281-011-0290-8
9. Chavakis T, Boeckel N, Santoso S, Voss R, Isordia-Salas I, Pixley RA, et al. Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogen. J Biol Chem (2002) 277(26):23157-64. doi:10.1074/jbc. M202529200
10. Chavakis T, Pixley RA, Isordia-Salas I, Colman RW, Preissner KT. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function. J Biol Chem (2002) 277(36):32677-82. doi:10.1074/jbc. M204010200
11. Chavakis T, Kanse SM, Pixley RA, May AE, Isordia-Salas I, Colman RW, et al. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J (2001) 15(13):2365-76. doi:10.1096/fj.01-0201com
12. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev (2005) 57(1):27-77. doi:10.1124/pr.57.1.2
13. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature (2008) 451(7182):1076-81. doi:10.1038/nature06559
14. Davalos D, Baeten KM, Whitney MA, Mullins ES, Friedman B, Olson ES, et al. Early detection of thrombin activity in neuroinflammatory disease. Ann Neurol (2014) 75(2):303-8. doi:10.1002/ana.24078
15. Gobel K, Pankratz S, Asaridou CM, Herrmann AM, Bittner S, Merker M, et al. Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun (2016) 7:11626. doi:10.1038/ncomms11626
16. Gobel K, Kraft P, Pankratz S, Gross CC, Korsukewitz C, Kwiecien R, et al. Prothrombin and factor X are elevated in multiple sclerosis patients. Ann Neurol (2016) 80(6):946-51. doi:10.1002/ana.24807
17. Prat A, Weinrib L, Becher B, Poirier J, Duquette P, Couture R, et al. Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology (1999) 53(9):2087-92. doi:10.1212/WNL.53.9.2087
18. Prat A, Biernacki K, Pouly S, Nalbantoglu J, Couture R, Antel JP. Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol (2000) 59(10):896-906. doi:10.1093/jnen/59.10.896
19. Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res (2010) 125(3):210-5. doi:10.1016/j.thromres.2009.11.028
20. Schmaier AH. The elusive physiologic role of Factor XII. J Clin Invest (2008) 118(9):3006-9. doi:10.1172/JCI36617
21. Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood (2012) 120(22):4296-303. doi:10.1182/blood-2012-07-292094
22. Spronk HM, Dielis AW, Panova-Noeva M, van Oerle R, Govers-Riemslag JW, Hamulyak K, et al. Monitoring thrombin generation: is addition of corn trypsin inhibitor needed? Thromb Haemost (2009) 101(6):1156-62. doi:10.1160/TH08-10-0670
23. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med (2006) 203(3):513-8. doi:10.1084/jem.20052458
24. Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation (2010) 121(13):1510-7. doi:10.1161/CIRCULATIONAHA.109.924761
25. Gobel K, Pankratz S, Schneider-Hohendorf T, Bittner S, Schuhmann MK, Langer HF, et al. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun (2011) 36(2):106-14. doi:10.1016/j.jaut.2010.11.004
26. Schulze-TopphoffU, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med (2009) 15(7):788-93. doi:10.1038/nm.1980
27. Dutra RC, Leite DF, Bento AF, Manjavachi MN, Patricio ES, Figueiredo CP, et al. The role of kinin receptors in preventing neuroinflammation and its clinical severity during experimental autoimmune encephalomyelitis in mice. PLoS One (2011) 6(11):e27875. doi:10.1371/journal.pone.0027875
28. Dutra RC, Bento AF, Leite DF, Manjavachi MN, Marcon R, Bicca MA, et al. The role of kinin B1 and B2 receptors in the persistent pain induced by experimental autoimmune encephalomyelitis (EAE) in mice: evidence for the involvement of astrocytes. Neurobiol Dis (2013) 54:82-93. doi:10.1016/j.nbd.2013.02.007
29. Dos Santos AC, Roffe E, Arantes RM, Juliano L, Pesquero JL, Pesquero JB, et al. Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice. J Neuroinflammation (2008) 5:49. doi:10.1186/1742-2094-5-49
30. Urich E, Gutcher I, Prinz M, Becher B. Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc Natl Acad Sci U S A (2006) 103(49):18697-702. doi:10.1073/pnas.0607283103
31. Nataf S, Carroll SL, Wetsel RA, Szalai AJ, Barnum SR. Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol (2000) 165(10):5867-73. doi:10.4049/jimmunol.165.10.5867
32. Calida DM, Constantinescu C, Purev E, Zhang GX, Ventura ES, Lavi E, et al. Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice. J Immunol (2001) 166(2):723-6. doi:10.4049/jimmunol.166.2.723
33. Szalai AJ, Hu X, Adams JE, Barnum SR. Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol Immunol (2007) 44(12):3132-6. doi:10.1016/j.molimm.2007.02.002
34. Smith SS, Ludwig M, Wohler JE, Bullard DC, Szalai AJ, Barnum SR. Deletion of both ICAM-1 and C3 enhances severity of experimental autoimmune encephalomyelitis compared to C3-deficient mice. Neurosci Lett (2008) 442(2):158-60. doi:10.1016/j.neulet.2008.07.005
35. Weerth SH, Rus H, Shin ML, Raine CS. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am J Pathol (2003) 163(3):1069-80. doi:10.1016/S0002-9440(10)63466-9
36. Niculescu T, Weerth S, Niculescu F, Cudrici C, Rus V, Raine CS, et al. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J Immunol (2004) 172(9):5702-6. doi:10.4049/jimmunol.172.9.5702
37. Reiman R, Campos Torres A, Martin BK, Ting JP, Campbell IL, Barnum SR. Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis. Neurosci Lett (2005) 390(3):134-8. doi:10.1016/j.neulet.2005.08.022
38. Gur-Wahnon D, Mizrachi T, Maaravi-Pinto FY, Lourbopoulos A, Grigoriadis N, Higazi AA, et al. The plasminogen activator system: involvement in central nervous system inflammation and a potential site for therapeutic intervention. J Neuroinflammation (2013) 10:124. doi:10.1186/1742-2094-10-124
39. East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gveric D. A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol (2005) 167(2):545-54. doi:10.1016/S0002-9440(10)62996-3
40. Prat A, Biernacki K, Saroli T, Orav JE, Guttmann CR, Weiner HL, et al. Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol (2005) 62(5):795-800. doi:10.1001/archneur.62.5.795
41. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem (2005) 70:247-99. doi:10.1016/S0065-3233(05)70008-5
42. Fuss C, Palmaz JC, Sprague EA. Fibrinogen: structure, function, and surface interactions. J Vasc Interv Radiol (2001) 12(6):677-82. doi:10.1016/S1051-0443(07)61437-7
43. Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost (1999) 25(3):311-9. doi:10.1055/s-2007-994933
44. Sidelmann JJ, Gram J, Jespersen J, Kluft C. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost (2000) 26(6):605-18. doi:10.1055/s-2000-13216
45. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci (2001) 936:226-36. doi:10.1111/j.1749-6632.2001.tb03511.x
46. East E, Gveric D, Baker D, Pryce G, Lijnen HR, Cuzner ML. Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation. Neuropathol Appl Neurobiol (2008) 34(2):216-30. doi:10.1111/j.1365-2990.2007.00889.x
47. Adams RA, Passino M, Sachs BD, Nuriel T, Akassoglou K. Fibrin mechanisms and functions in nervous system pathology. Mol Interv (2004) 4(3):163-76. doi:10.1124/mi.4.3.6
48. Tennent GA, Brennan SO, Stangou AJ, O'Grady J, Hawkins PN, Pepys MB. Human plasma fibrinogen is synthesized in the liver. Blood (2007) 109(5):1971-4. doi:10.1182/blood-2006-08-040956
49. Lowe GD. Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients: not yet. J Thromb Haemost (2005) 3(4):635-7. doi:10.1111/j.1538-7836.2005.01256.x
50. Solovjov DA, Pluskota E, Plow EF. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem (2005) 280(2):1336-45. doi:10.1074/jbc. M406968200
51. Perez RL, Roman J. Fibrin enhances the expression of IL-1 beta by human peripheral blood mononuclear cells. Implications in pulmonary inflammation. J Immunol (1995) 154(4):1879-87
52. Perez RL, Ritzenthaler JD, Roman J. Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am J Respir Cell Mol Biol (1999) 20(5):1059-66. doi:10.1165/ajrcmb.20.5.3281
53. Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest (2007) 117(11):3224-35. doi:10.1172/JCI30134
54. Steinbrecher KA, Horowitz NA, Blevins EA, Barney KA, Shaw MA, Harmel-Laws E, et al. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res (2010) 70(7):2634-43. doi:10.1158/0008-5472.CAN-09-3465
55. Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, Tang Z, et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res (2012) 110(9):1202-10. doi:10.1161/CIRCRESAHA.111.256370
56. Wakefield AJ, More LJ, Difford J, McLaughlin JE. Immunohistochemical study of vascular injury in acute multiple sclerosis. J Clin Pathol (1994) 47(2):129-33. doi:10.1136/jcp.47.2.129
57. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain (1997) 120(Pt 8):1461-83. doi:10.1093/brain/120.8.1461
58. Adams RA, Bauer J, Flick MJ, Sikorski SL, Nuriel T, Lassmann H, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med (2007) 204(3):571-82. doi:10.1084/jem.20061931
59. Ryu JK, Petersen MA, Murray SG, Baeten KM, Meyer-Franke A, Chan JP, et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun (2015) 6:8164. doi:10.1038/ncomms9164
60. Akassoglou K, Adams RA, Bauer J, Mercado P, Tseveleki V, Lassmann H, et al. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci U S A (2004) 101(17):6698-703. doi:10.1073/pnas.0303859101
61. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest (2004) 113(11):1596-606. doi:10.1172/JCI20741
62. Paterson PY. Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed Proc (1976) 35(13):2428-34
63. Yang Y, Tian SJ, Wu L, Huang DH, Wu WP. Fibrinogen depleting agent batroxobin has a beneficial effect on experimental autoimmune encephalomyelitis. Cell Mol Neurobiol (2011) 31(3):437-48. doi:10.1007/s10571-010-9637-2
64. Inoue A, Koh CS, Shimada K, Yanagisawa N, Yoshimura K. Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats. J Neuroimmunol (1996) 71(1-2):131-7. doi:10.1016/S0165-5728(96)00150-6
65. Sibley WA, Kiernat J, Laguna JF. The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid. Neurology (1978) 28(9 Pt 2):102-5. doi:10.1212/WNL.28.9_Part_2.102
66. Lu W, Bhasin M, Tsirka SE. Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J Neurosci (2002) 22(24):10781-9. doi:10.1523/JNEUROSCI.22-24-10781.2002
67. Xie C, Alcaide P, Geisbrecht BV, Schneider D, Herrmann M, Preissner KT, et al. Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus. J Exp Med (2006) 203(4):985-94. doi:10.1084/jem.20051681
68. Paterson PY. Experimental allergic encephalomyelitis-inducing activity of synthetic polyadenylic and polyuridylic homopolymers and complexes in guinea pigs. Cell Immunol (1976) 21(1):48-55. doi:10.1016/0008-8749(76)90326-9
69. Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, Cuzner ML. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain (2001) 124(Pt 10):1978-88. doi:10.1093/brain/124.10.1978
70. Gveric D, Herrera B, Petzold A, Lawrence DA, Cuzner ML. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain (2003) 126(Pt 7):1590-8. doi:10.1093/brain/awg167
71. Akenami FO, Siren V, Koskiniemi M, Siimes MA, Teravainen H, Vaheri A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol (1996) 49(7):577-80. doi:10.1136/jcp.49.7.577
72. Mazodier K, Arnaud L, Mathian A, Costedoat-Chalumeau N, Haroche J, Frances C, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore) (2012) 91(5):251-60. doi:10.1097/MD.0b013e31826b971f
73. Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency: an update. Semin Thromb Hemost (2013) 39(6):596-606. doi:10.1055/s-0033-1348948
74. Hirano K, Hirano M. Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage. J Pharmacol Sci (2010) 114(2):127-33. doi:10.1254/jphs.10R03CP
75. Beilin O, Karussis DM, Korczyn AD, Gurwitz D, Aronovich R, Hantai D, et al. Increased thrombin inhibition in experimental autoimmune encephalomyelitis. J Neurosci Res (2005) 79(3):351-9. doi:10.1002/jnr.20270
76. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet (2001) 358(9285):903-11. doi:10.1016/S0140-6736(01)06075-5
77. So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Peclat V, Gerster JC, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost (2003) 1(12):2510-5. doi:10.1111/j.1538-7836.2003.00462.x
78. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun (2008) 31(2):175-9. doi:10.1016/j.jaut.2008.07.002
79. Liu X, Piela-Smith TH. Fibrin(ogen)-induced expression of ICAM-1 and chemokines in human synovial fibroblasts. J Immunol (2000) 165(9):5255-61. doi:10.4049/jimmunol.165.9.5255
80. Varisco PA, Peclat V, van Ness K, Bischof-Delaloye A, So A, Busso N. Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis. Ann Rheum Dis (2000) 59(10):781-7. doi:10.1136/ard.59.10.781
81. Marty I, Peclat V, Kirdaite G, Salvi R, So A, Busso N. Amelioration of collagen-induced arthritis by thrombin inhibition. J Clin Invest (2001) 107(5):631-40. doi:10.1172/JCI11064
82. Kwiecinski J, Josefsson E, Jin T. Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease. Inflamm Res (2011) 60(11):1021-9. doi:10.1007/s00011-011-0363-0
83. Xie Z, Dai J, Yang A, Wu Y. A role for bradykinin in the development of anti-collagen antibody-induced arthritis. Rheumatology (Oxford) (2014) 53(7):1301-6. doi:10.1093/rheumatology/keu015
84. Espinola RG, Uknis A, Sainz IM, Isordia-Salas I, Pixley R, DeLa Cadena R, et al. A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. Am J Pathol (2004) 165(3):969-76. doi:10.1016/S0002-9440(10)63358-5
85. Keith JC Jr, Sainz IM, Isordia-Salas I, Pixley RA, Leathurby Y, Albert LM, et al. A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat. Arthritis Res Ther (2005) 7(4):R769-76. doi:10.1186/ar1728
86. Sainz IM, Isordia-Salas I, Castaneda JL, Agelan A, Liu B, DeLa Cadena RA, et al. Modulation of inflammation by kininogen deficiency in a rat model of inflammatory arthritis. Arthritis Rheum (2005) 52(8):2549-52. doi:10.1002/art.21202
87. Valenti C, Giuliani S, Cialdai C, Tramontana M, Maggi CA. Anti-inflammatory synergy of MEN16132, a kinin B(2) receptor antagonist, and dexamethasone in carrageenan-induced knee joint arthritis in rats. Br J Pharmacol (2010) 161(7):1616-27. doi:10.1111/j.1476-5381.2010.00995.x
88. Dela Cadena RA, Stadnicki A, Uknis AB, Sartor RB, Kettner CA, Adam A, et al. Inhibition of plasma kallikrein prevents peptidoglycan-induced arthritis in the Lewis rat. FASEB J (1995) 9(5):446-52. doi:10.1096/fasebj.9.5.7896018
89. Fujimori Y, Nakamura T, Shimizu K, Yamamuro T, Wanaka K, Okamoto S, et al. Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice. Agents Actions (1993) 39(1-2):42-8. doi:10.1007/BF01975713
90. Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest (1998) 102(1):41-50. doi:10.1172/JCI2312
91. Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol (2005) 166(3):783-92. doi:10.1016/S0002-9440(10)62299-7
92. Li J, Guo Y, Holmdahl R, Ny T. Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. Arthritis Rheum (2005) 52(8):2541-8. doi:10.1002/art.21229
93. Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol (2001) 167(2):1047-52. doi:10.4049/jimmunol.167.2.1047
94. Cook AD, Braine EL, Campbell IK, Hamilton JA. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol (2002) 160(3):917-26. doi:10.1016/S0002-9440(10)64914-0
95. Cook AD, De Nardo CM, Braine EL, Turner AL, Vlahos R, Way KJ, et al. Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement. Arthritis Res Ther (2010) 12(2):R37. doi:10.1186/ar2946
96. De Nardo CM, Lenzo JC, Pobjoy J, Hamilton JA, Cook AD. Urokinase-type plasminogen activator and arthritis progression: contrasting roles in systemic and monoarticular arthritis models. Arthritis Res Ther (2010) 12(5):R199. doi:10.1186/ar3171
97. McLaren M, Alkaabi J, Connacher M, Belch JJ, Valenete E. Activated factor XII in rheumatoid arthritis. Rheumatol Int (2002) 22(5):182-4. doi:10.1007/s00296-002-0219-6
98. Uknis AB, DeLa Cadena RA, Janardham R, Sartor RB, Whalley ET, Colman RW. Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat. Inflamm Res (2001) 50(3):149-55. doi:10.1007/s000110050739
99. Devani M, Cugno M, Vecchi M, Ferrero S, Di Berardino F, Avesani EC, et al. Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers. Am J Gastroenterol (2002) 97(8):2026-32. doi:10.1111/j.1572-0241.2002.05919.x
100. Dolapcioglu C, Soylu A, Kendir T, Ince AT, Dolapcioglu H, Purisa S, et al. Coagulation parameters in inflammatory bowel disease. Int J Clin Exp Med (2014) 7(5):1442-8
101. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol (2008) 14(3):378-89. doi:10.3748/wjg.14.378